Cerus Corporation (CERS) Financial Analysis & Valuation | Quarter Chart

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pa... more
Cerus Corporation operates as a biomedical products company. The company focuses on developing and c... more

Company facts

Reported company information and share structure.

Company Share structure
Market Cap$517.92MExchangeNASDAQ
SectorHealthcareIndustryMedical - Devices
CountryUSCEOVivek K. Jayaraman
IPO Date1997-01-31CAGR12.9%
Employees268Websitewww.cerus.com
Div. YieldPayout Ratio
Buy Back YieldTotal Yield
CERS chart loading...

Key metrics

Reported fundamentals and market-derived technical indicators.

Fundamentals Technicals
EV$687.44MP/E-51.3Forward P/E-514PEG
P/S208.43P/B663.31P/CF19419.47P/FCF-26051.38
Sales$227.78MSales 1Y18.32%Sales 3Y48.46%Sales 5Y113.54%
EPS$-0.05EPS 1Y-68.63%EPS 3Y-88.99%EPS 5Y-91.26%
Sales QoQ-4.09%EPS QoQSales QoQ Avg2.42%EPS QoQ Avg2797.01%
Gross Margin53.36%Operating Margin-3.71%Profit Margin-2.98%ROCE-7.07%
ROA-3%ROE-10%Altman Z Score-2.89Piotroski Score4
Current Ratio1.83Quick Ratio1.07Cash Ratio0.21Op. CF Ratio-0.03
Debt/Equity0.59Debt/Assets0.2Lt Debt/Equity0.12Lt Debt/Cap.0.11
Intrst Cov.-2.07Inventory Turnover1.61Asset Turnover1.11Receivables Turnover7.35
Enterprise Value$687.44MP/E Ratio-51.3
Forward P/E-514PEG Ratio
P/S Ratio208.43P/B Ratio663.31
P/CF Ratio19419.47P/FCF Ratio-26051.38
EPS$-0.05EPS Growth 1Y-68.63%
EPS Growth 3Y-88.99%EPS Growth 5Y-91.26%
Revenue Growth 1Y18.32%Gross Margin0.53%
Operating Margin-0.04%Profit Margin-0.03%
ROE-0.1%ROA-0.03%
ROCE-0.07%Current Ratio1.83
Quick Ratio1.07Cash Ratio0.21
Debt/Equity0.59Interest Coverage-2.07
Altman Z Score-2.89Piotroski Score4

Cerus Corporation (CERS) valuation & financials

Cerus Corporation (CERS) has a market capitalization of $517.92M and trades at a price-to-earnings ratio of -51.3. It operates in the Healthcare sector (Medical - Devices).

Cerus Corporation's revenue grew +18.3% over the last year.

Cerus Corporation's next earnings report is scheduled for November 5, 2026 after market close; analysts estimate EPS of $-0.01. Check the earnings calendar to see all companies reporting this week.

📈 Analysts estimate CERS EPS of $-0.01 for the upcoming quarter. See Cerus Corporation revenue & EPS analyst forecasts for the next four quarters with Quarter Chart Premium.

Cerus Corporation (CERS) — frequently asked questions

When does Cerus Corporation (CERS) report earnings next?

Cerus Corporation is expected to report earnings on November 5, 2026 after market close. Analysts estimate EPS of $-0.01.

What is Cerus Corporation's market cap?

Cerus Corporation (CERS) has a market capitalization of $517.92M.

What is CERS's P/E ratio?

Cerus Corporation trades at a price-to-earnings ratio of -51.3, with trailing twelve-month EPS of $-0.05.

How fast is Cerus Corporation growing?

Cerus Corporation's revenue grew +18.3% over the last year.

Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)